Rapid Micro Biosystems, Inc.
- Open
- 1.75
- Day high
- 1.75
- Day low
- 1.72
- Prev close
- 1.73
- Volume
- 32K
- Mkt cap
- $79M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 3.9
- P/S
- 2.3
- Yield
- —
- Per share
- —
- ▲Insiders net buying $15K over the last 3 months (1 open-market buy, 0 sales)
- 🏛Institutions accumulating (13F)
Rapid Micro Biosystems, Inc. (RPID) is a Healthcare company listed on NASDAQ. The stock is down 50% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 0 sales (SEC Form 4).
Rapid Micro Biosystems, Inc. (RPID) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
RPID earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 13, 2026 | $-0.25 | $-0.31 | -24.0% | $8M | +5.3% |
| Mar 12, 2026 | $-0.23 | $-0.28 | -23.6% | $11M | +3.2% |
| Nov 7, 2025 | $-0.26 | $-0.26 | +0.0% | $8M | -28.3% |
| Aug 12, 2025 | $-0.26 | $-0.27 | -3.8% | $7M | -12.9% |
| May 9, 2025 | $-0.27 | $-0.26 | +3.7% | $7M | +4.9% |
| Feb 28, 2025 | $-0.22 | $-0.22 | +0.0% | $8M | +0.2% |
| Nov 1, 2024 | $-0.26 | $-0.26 | +0.0% | $8M | +0.1% |
| Aug 2, 2024 | $-0.28 | $-0.29 | -3.6% | $7M | +1.0% |
| May 3, 2024 | $-0.29 | $-0.31 | -6.9% | $6M | -6.5% |
| Mar 1, 2024 | $-0.31 | $-0.26 | +16.1% | $6M | +15.2% |
| Nov 3, 2023 | $-0.32 | $-0.31 | +3.1% | $6M | -1.7% |
| Aug 4, 2023 | $-0.36 | $-0.33 | +8.3% | $5M | -9.9% |
RPID insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 2, 2026 | PEI MELINDA LITHERLANDdirector | Grant | 12,787 | $1.96 |
| Jun 2, 2026 | Spignesi Robert G. Jr.director, officer: PRESIDENT AND CEO | Grant | 12,787 | $1.96 |
| Jun 2, 2026 | WIRTJES SEAN Mofficer: CHIEF FINANCIAL OFFICER | Grant | 12,787 | $1.96 |
| Jun 2, 2026 | Malloy Kirkdirector | Grant | 12,787 | $1.96 |
| Jun 2, 2026 | LOWENSTEIN INESEdirector | Grant | 12,787 | $1.96 |
| May 26, 2026 | LOWENSTEIN INESEdirector | Grant | 38,700 | $2.07 |
| May 26, 2026 | PEI MELINDA LITHERLANDdirector | Grant | 38,700 | $2.07 |
| May 26, 2026 | Kollender Richard Sdirector | Grant | 19,300 | — |
| May 26, 2026 | Kollender Richard Sdirector | Grant | 38,700 | $2.07 |
| May 26, 2026 | Bika Dafnidirector | Grant | 38,700 | $2.07 |
| May 26, 2026 | Bika Dafnidirector | Grant | 19,300 | — |
| May 26, 2026 | Malloy Kirkdirector | Grant | 19,300 | — |
| May 26, 2026 | Malloy Kirkdirector | Grant | 38,700 | $2.07 |
| May 26, 2026 | LOWENSTEIN INESEdirector | Grant | 19,300 | — |
| May 26, 2026 | PEI MELINDA LITHERLANDdirector | Grant | 19,300 | — |
Source: RPID SEC Form 4 filings, latest Jun 2, 2026. For informational purposes only — not investment advice.
See the full RPID insider & 13F page →Rapid Micro Biosystems, Inc. company profile
Overview
Rapid Micro Biosystems, Inc. (NASDAQ:RPID) is a life sciences technology company founded in 2006 and headquartered in Lowell, Massachusetts. Originally incorporated as Genomic Profiling Systems, Inc., the company changed its name to Rapid Micro Biosystems in January 2007 and went public in July 2021. The company specializes in automating microbial quality control testing for pharmaceutical, medical device, and personal care manufacturers through its flagship Growth Direct platform, which modernizes traditional manual testing workflows that have remained largely unchanged for decades.
Business
Rapid Micro Biosystems operates in the microbial quality control (MQC) testing industry, which is a critical component of pharmaceutical and medical device manufacturing. The company's core offering is the Growth Direct platform, an automated system that revolutionizes how manufacturers detect microbial contamination in their products and manufacturing environments. Traditional microbial testing in pharmaceutical manufacturing relies on manual processes that can take days or weeks to produce results. Technicians must manually prepare culture media, inoculate samples, incubate them, and visually inspect for microbial growth. This process is labor-intensive, prone to human error, and creates significant delays in production cycles. The Growth Direct system automates this entire workflow by using advanced imaging technology and software algorithms to detect and identify microbial growth in real-time, reducing testing time from days to hours. The Growth Direct platform consists of several integrated components: 1. The Growth Direct system hardware that houses the automated imaging and incubation technology, 2. Proprietary consumables including specialized plates and reagents designed specifically for the system, 3. Lab information management system (LIMS) connection software that integrates with customers' existing data management infrastructure, and 4. Comprehensive validation and support services to ensure regulatory compliance and optimal system performance. The company's solutions are used across multiple testing applications including environmental monitoring (testing air, surfaces, and water in manufacturing facilities), bioburden testing (measuring microbial load in raw materials and intermediate products), and sterility release testing (confirming final products are free from viable microorganisms). These applications are particularly critical for therapeutic modalities such as biologics, vaccines, cell and gene therapies, and sterile injectables, where microbial contamination can be life-threatening. Recently, the company has expanded its product portfolio with Rapid Sterility, a specialized application for sterility testing, and RMBNucleus Mold Alarm, software that provides enhanced detection capabilities for mold contamination. The company generates revenue through both product sales (systems and consumables) and ongoing services, with recurring revenue representing a significant portion of the business model.
Revenue model
Rapid Micro Biosystems operates a capital equipment and consumables business model similar to the traditional "razor and blade" approach. The company generates revenue through three primary streams: system sales, consumable sales, and service revenue. System sales represent the initial capital equipment purchase, where customers buy the Growth Direct hardware platform. These are typically high-value transactions ranging from hundreds of thousands to over a million dollars per system, depending on configuration and customer requirements. The company has placed 162 systems cumulatively as of Q4 2024, with customers including 70% of the world's top 20 pharmaceutical manufacturers. Consumable sales provide the recurring revenue foundation of the business model. Each Growth Direct system requires proprietary consumables including specialized plates, reagents, and other testing materials that must be regularly replenished. This creates a predictable, recurring revenue stream that grows with system utilization. Consumable revenue has shown consistent growth, increasing over 30% in recent quarters, and represents a higher-margin business compared to system sales. Service revenue includes installation, validation, technical training, ongoing support, and software subscriptions. The company provides comprehensive validation services to ensure customers meet regulatory requirements from agencies like the FDA and EMA. This service component is particularly valuable given the highly regulated nature of pharmaceutical manufacturing, where proper validation and documentation are critical for regulatory approval. The company's customers are primarily large pharmaceutical manufacturers, biotechnology companies, and medical device manufacturers who require microbial testing as part of their quality control processes. These customers typically have substantial budgets for quality control equipment and face significant regulatory pressure to maintain sterile manufacturing environments. Several factors influence the company's margins and profitability. Positive factors include the growing pharmaceutical manufacturing capacity (with an estimated $150 billion in global investment), increasing adoption of advanced therapeutics like biologics and cell/gene therapies that require more sophisticated testing, and the company's focus on operational efficiency and cost reduction initiatives. The recent partnership with MilliporeSigma also provides opportunities for improved supply chain efficiency and market expansion. Negative factors include the complex and lengthy sales cycles typical in pharmaceutical equipment purchases, the significant upfront investment required for system validation and installation, competitive pressure from established players in the microbial testing market, and the company's current cash burn rate while scaling operations. Additionally, economic uncertainty can impact customer capital expenditure decisions, potentially delaying system purchases even when the value proposition is clear.
Competitive moat
Rapid Micro Biosystems possesses a moderate competitive moat built primarily on technological differentiation, regulatory barriers, and switching costs, though this moat faces ongoing challenges from established competitors and the inherent conservatism of pharmaceutical manufacturers. The company's primary moat stems from its proprietary technology platform that automates traditionally manual processes. The Growth Direct system's real-time imaging and detection capabilities represent a significant technological advancement over conventional microbial testing methods. This technology is protected by intellectual property and requires specialized expertise to develop and maintain, creating barriers for new entrants. Regulatory validation represents another significant moat component. Pharmaceutical manufacturers must validate any new testing equipment through extensive regulatory processes that can take months or years to complete. Once a Growth Direct system is validated and integrated into a customer's quality control processes, the switching costs become substantial. Customers must invest significant time and resources in validation, staff training, and process integration, making them reluctant to change systems without compelling reasons. The company benefits from high customer switching costs beyond regulatory validation. The Growth Direct platform integrates with customers' existing LIMS and quality management systems, creating operational dependencies. Additionally, the consumables model creates ongoing customer relationships and recurring touchpoints that strengthen customer retention. However, the company's moat faces meaningful challenges. Established competitors like Thermo Fisher Scientific, Merck KGaA, and other large life sciences companies have significantly greater resources, broader product portfolios, and deeper customer relationships. These competitors can leverage their existing market presence and customer relationships to compete effectively, even if their technology is not as advanced. The conservative nature of pharmaceutical manufacturing also limits the moat's effectiveness. Pharmaceutical companies are inherently risk-averse and often prefer established, proven solutions over newer technologies, even when the newer technology offers clear advantages. This conservatism can slow adoption and limit the company's ability to capture market share quickly. Additionally, the company's financial constraints limit its ability to invest heavily in R&D, marketing, and customer acquisition compared to larger competitors. With ongoing cash burn and limited resources, the company must carefully balance growth investments with financial sustainability, potentially limiting its ability to strengthen its competitive position over time.
Risks & safety
Rapid Micro Biosystems presents a moderate to high-risk investment profile with limited margin of safety due to ongoing cash burn, though the company maintains adequate liquidity for near-term operations. Liquidity and Solvency: - Cash and short-term investments: $18.9 million as of Q1 2025 - Current ratio: 4.61x indicating strong short-term liquidity - Debt-to-equity ratio: 0.09x showing minimal debt burden - Annual cash burn: Approximately $30 million expected for 2025 - Cash runway: Approximately 18-24 months at current burn rate Valuation Metrics: - Price-to-book ratio: 1.77x (Q1 2025) - Enterprise value to EBITDA: Negative due to losses - Graham net-net ratio: 0.81x suggesting potential asset value - Revenue multiple: Trading at approximately 5.7x forward revenue guidance Other Considerations: - Company has never achieved profitability since going public - Operational efficiency program targeting $7 million annual cost reduction - Strong balance sheet with minimal debt provides financial flexibility - Revenue growth trajectory positive but cash flow negative - Dependence on continued access to capital markets for long-term sustainability
Recent development
Over the past few years, Rapid Micro Biosystems has focused on several key strategic initiatives to accelerate growth and improve operational efficiency. The company has significantly expanded its product portfolio beyond the core Growth Direct platform, launching the Rapid Sterility application for sterility testing and the RMBNucleus Mold Alarm software for enhanced mold detection capabilities. These additions allow the company to address broader testing workflows within existing customer facilities and attract new customer segments. A major strategic development was the global distribution and collaboration agreement with MilliporeSigma signed in late 2024. This partnership provides co-exclusive global rights to sell the Growth Direct system and includes a commitment from MilliporeSigma to purchase a minimum number of systems. The collaboration is expected to accelerate market penetration, particularly in adjacent markets like personal care, cosmetics, and medical devices, while potentially improving supply chain efficiency and gross margins. The company has implemented a comprehensive operational efficiency program targeting approximately $7 million in annual cost reductions. This initiative includes workforce optimization and non-headcount expense reductions while maintaining the commercial team's capability to support the full product range. The program aims to achieve positive cash flow by the end of 2027 without requiring additional financing. From a commercial perspective, the company has made significant progress in customer acquisition and system placements. The company has successfully placed systems with 70% of the world's top 20 pharmaceutical manufacturers and has achieved 162 cumulative system placements globally, with 137 fully validated. The company has also enhanced its sales processes and customer experience, expanded focus on key accounts, and added experienced commercial leadership. Gross margin improvement has been a critical focus area, with the company achieving positive gross margins for the first time in Q3 2024 at 8%, improving to 12% in Q4 2024. This improvement reflects ongoing cost reduction efforts, manufacturing efficiency gains, and better product mix optimization. The company expects to achieve high single-digit to low double-digit gross margins consistently going forward.
RPID company profile · for informational purposes only — not investment advice.
Track RPID with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free